Clinical Trials Browser

Phase 1/2 × Capsules × 90 days × Clear all

NCT02629692 2026-05-13

Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies

Phase 1/2 Terminated

124 enrolled 51 charts

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive